[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653363":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":11,"studyPopulation":28,"armGroups":11,"interventions":29,"overallOfficials":11,"centralContacts":11,"locations":34,"responsibleParty":53,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":11,"maxAge":11,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":11,"briefSummary":69,"conditions":70,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Hanmi Pharmaceutical Company Limited","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The change in Systolic Blood Pressure (SBP) relative to baseline",null,"the 6-month time",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"effectiveness of sequential triple combination therapy (amlodipine\u002Flosartan\u002Fchlorthalidone)","Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 2 and 4 months, and change from baseline in DBP at 6 months","2, 4, 6 months",{"measure":19,"description":20,"timeFrame":17},"Prescription patterns of a triple-therapy-based stepwise treatment strategy","Proportion of Participants by Study Drug Dosage at Months 2, 4, and 6",{"measure":22,"description":23,"timeFrame":24},"safety of sequential triple combination therapy (amlodipine\u002Flosartan\u002Fchlorthalidone)","Incidence of Adverse Events During the 6-Month Follow-up Period","2, 4 , 6 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":26,"timePerspective":27,"maskingInfo":11},"COHORT","PROSPECTIVE","General hospital",[30],{"type":31,"name":32,"description":33,"armGroupLabels":11,"otherNames":11},"DRUG","AMOPREL TAB 1.67\u002F16.67\u002F4.17mg","Follow-up of subjects prescribed medication in a non-intervention study",[35],{"facility":36,"status":37,"city":38,"state":11,"zip":39,"country":40,"countryCode":11,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Yongin Severance Hospital","RECRUITING","Gyeonggi-do","16995","South Korea",{"type":42,"coordinates":43},"Point",[44,45],126.76917,37.58944,{"lat":45,"lon":44},[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"PM","CONTACT","+8224109291","juyoung.lee@hanmi.co.kr",{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100653363","effectiveness-and-safety-of-sequential-triple-combination-therapy-amlodipinelosartanchlorthalidone-in-korean-patients-with-hypertension-100653363",false,"NCT07784296","Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine\u002FLosartan\u002FChlorthalidone) in Korean Patients With Hypertension","A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine\u002FLosartan\u002FChlorthalidone) in Korean Patients With Hypertension","AMPR-OS-2503","Inclusion Criteria:\n\n1. Korean patients aged 19 years or older diagnosed with hypertension\n2. Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug\n3. Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment\n4. Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study\n\nExclusion Criteria:\n\n1. Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab.\n2. Pregnant women, women who may be pregnant, and nursing mothers\n3. Individuals currently participating in an interventional study\n4. Individuals deemed unsuitable for participation in this study by the researcher for other reasons","ALL",{"count":65,"type":66},3500,"ESTIMATED","6 Months","OBSERVATIONAL","A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine\u002Flosartan\u002Fchlorthalidone) in Korean patients with hypertension",[71],"Hypertension","2026-08-20",{"date":74,"type":75},"2026-08-25","ACTUAL",{"date":77,"type":75},"2026-03-19",{"date":79,"type":66},"2028-08-31",{"name":5,"class":6},1]